Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancer

被引：2
|
作者：
Torres, Alexandra
Kokkonen, Carey
Oladeji, Mary
D'Andrea, Kurt
Mick, Rosemarie
Narayan, Vivek
Mallamaci, Michael
Ewing, Gayle
Knollman, Hayley
Tung, Nadine M.
Robson, Mark
Nathanson, Katherine L.
Domchek, Susan
Shah, Payal D.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-OT2-18-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-18-01
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE)
    Torres, Alexandra
    Aaron, Megan
    White, Lia
    D'Andrea, Kurt
    Narayan, Vivek
    Knollman, Hayley Michelle
    Bradbury, Angela R.
    Tung, Nadine M.
    Robson, Mark E.
    Nathanson, Katherine
    Domchek, Susan M.
    Shah, Payal Deepak
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2-metastatic breast cancer
    Shah, Payal Deepak
    Torres, Alexandra
    Aaron, Megan
    Narayan, Vivek
    Knollman, Hayley Michelle
    Bradbury, Angela R.
    DeMichele, Angela
    Robson, Mark E.
    Tung, Nadine M.
    Domchek, Susan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Hugo Herrscher
    Michel Velten
    Julie Leblanc
    Michal Kalish-Weindling
    Cathie Fischbach
    Delphine Exinger
    Xavier Pivot
    Thierry Petit
    Breast Cancer Research and Treatment, 2020, 179 : 371 - 376
  • [4] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Herrscher, Hugo
    Velten, Michel
    Leblanc, Julie
    Kalish-Weindling, Michal
    Fischbach, Cathie
    Exinger, Delphine
    Pivot, Xavier
    Petit, Thierry
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (02) : 371 - 376
  • [5] Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
    Schwartzberg, Lee S.
    Kiedrowski, Lesli A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [6] FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Walker, Amanda J.
    Wedam, Suparna
    Amiri-Kordestani, Laleh
    Bloomquist, Erik
    Tang, Shengui
    Sridhara, Rajeshwari
    Chen, Wei
    Palmby, Todd R.
    Zirkelbach, Jeanne Fourie
    Fu, Wentao
    Liu, Qi
    Tilley, Amy
    Kim, Geoffrey
    Kluetz, Paul G.
    McKee, Amy E.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (20) : 4968 - 4972
  • [7] Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
    Malorni, Luca
    Tyekucheva, Svitlana'
    Hilbers, Florentine S.
    Ignatiadis, Michail
    Neven, Patrick
    Colleoni, Marco
    Henry, Stephanie
    Ballestrero, Alberto
    Bonetti, Andrea
    Jerusalem, Guy
    Papadimitriou, Konstantinos
    Bernardo, Antonio
    Seles, Elena
    Duhoux, Francois P.
    MacPherson, Iain R.
    Thomson, Alastair
    Davies, David Mark
    Bergqvist, Mattias
    Migliaccio, Ilenia
    Gebhart, Geraldine
    Zoppoli, Gabriele
    Bliss, Judith M.
    Benelli, Matteo
    McCartney, Amelia
    Kammler, Roswitha
    De Swert, Heidi
    Ruepp, Barbara
    Fumagalli, Debora
    Maibach, Rudolf
    Cameron, David
    Loi, Sherene
    Piccart, Martine
    Regan, Meredith M.
    EUROPEAN JOURNAL OF CANCER, 2022, 164 : 39 - 51
  • [8] Circulating tumor cells in patients with hormone receptor-positive, HER2-negative metastatic breast cancer receiving palbociclib with fulvestrant after progression on palbociclib with an aromatase inhibitor
    Tao, Jessica
    Chen, Ruizhe
    Blackford, Amanda L.
    Cescon, Terrence
    Christou, Antonios
    Couzi, Rima
    Darga, Elizabeth
    Jones, Mary Kate
    Mahosky, Justin
    Nunes, Raquel
    Paoletti, Costanza
    Santa-Maria, Cesar Augusto
    Smith, Karen L.
    Truica, Cristina I.
    Werner, Jeanine
    Wolff, Antonio C.
    Stearns, Vered
    Hayes, Daniel F.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Alternative Palbociclib Dosing Schedules for Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer
    Go, Makiko
    Kimura, Michio
    Yamada, Shiori
    Kamei, Keitaro
    Noguchi, Yoshinori
    Usami, Eiseki
    Yoshimura, Tomoaki
    ONCOLOGY, 2024,
  • [10] Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
    Schettini, Francesco
    De Santo, Irene
    Rea, Carmen G.
    Viggiani, Martina
    Buono, Giuseppe
    De Angelis, Carmine
    Cardalesi, Cinzia
    Lauria, Rossella
    Giuliano, Mario
    Forestieri, Valeria
    Thomas, Guglielmo
    Maione, Pierfrancesco
    Limite, Gennaro
    Accurso, Antonello
    Malorni, Luca
    De Placido, Sabino
    Arpino, Grazia
    MOLECULAR AND CLINICAL ONCOLOGY, 2020, 12 (05) : 456 - 460
12345